Page contentsPage contents Key facts Decision Key facts Active substance efgartigimod alfa Therapeutic area Musculoskeletal and connective tissue disorders Decision number EMA/PE/0000225023 PIP number EMA/PE/0000225023 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Treatment of Sjögren's syndrome Route(s) of administration Intravenous useSubcutaneous use Contact for public enquiries Argenx E-mail: regulatory@argenx.com Tel. +32 93103400 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 03/01/2025 Compliance check done No Decision EMA/PE/0000225023 : EMA decision of 3 January 2025 on the granting of a product specific waiver for efgartigimod alfa (Vyvgart)Adopted Reference Number: EMADOC-1700519818-1810349 English (EN) (189.28 KB - PDF)First published: 12/03/2026 View Share this page